Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery
Public ClinicalTrials.gov record NCT00777491. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Randomized Study For Patients With Muscle-Invasive Bladder Cancer Evaluating Transurethral Surgery And Concomitant Chemoradiation By Either BID Irradiation Plus 5-Fluorouracil And Cisplatin Or QD Irradiation Plus Gemcitabine Followed By Selective Bladder Preservation And Gemcitabine/Cisplatin Adjuvant Chemotherapy
Study identification
- NCT ID
- NCT00777491
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Enrollment
- 70 participants
Conditions and interventions
Conditions
Interventions
- induction cisplatin Drug
- induction 5-fluorouracil Drug
- induction gemcitabine Drug
- Induction BID radiation therapy Radiation
- Induction QD radiation therapy Radiation
- Consolidation BID radiation therapy Radiation
- Consolidation QD radiation therapy Radiation
- consolidation gemcitabine Drug
- consolidation 5-fluorouracil Drug
- consolidation cisplatin Drug
- radical cystectomy Procedure
- Post-Induction Chemoradiotherapy Endoscopic Response Evaluation Procedure
- adjuvant gemcitabine Drug
- adjuvant cisplatin Drug
Drug · Radiation · Procedure
Eligibility (public fields only)
- Age range
- 18 Years to 120 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2008
- Primary completion
- Feb 17, 2018
- Completion
- May 19, 2022
- Last update posted
- Jun 14, 2022
2008 – 2022
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Georgia Cancer Center for Excellence at Grady Memorial Hospital | Atlanta | Georgia | 30303 | — |
| Winship Cancer Institute of Emory University | Atlanta | Georgia | 30322 | — |
| Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center | Boise | Idaho | 83706 | — |
| Cancer Institute at St. John's Hospital | Springfield | Illinois | 62702 | — |
| Parkview Regional Cancer Center at Parkview Health | Fort Wayne | Indiana | 46805 | — |
| St. Agnes Hospital Cancer Center | Baltimore | Maryland | 21229 | — |
| Hudner Oncology Center at Saint Anne's Hospital - Fall River | Fall River | Massachusetts | 02721 | — |
| Saint Joseph Mercy Cancer Center | Ann Arbor | Michigan | 48106-0995 | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109-0942 | — |
| West Michigan Cancer Center | Kalamazoo | Michigan | 49007-3731 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00777491, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 14, 2022 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00777491 live on ClinicalTrials.gov.